SG11201503684WA - Pyrimido [4,5-b]quinoline-4,5 (3h,10h)-diones as nonsense mutation suppressors - Google Patents
Pyrimido [4,5-b]quinoline-4,5 (3h,10h)-diones as nonsense mutation suppressorsInfo
- Publication number
- SG11201503684WA SG11201503684WA SG11201503684WA SG11201503684WA SG11201503684WA SG 11201503684W A SG11201503684W A SG 11201503684WA SG 11201503684W A SG11201503684W A SG 11201503684WA SG 11201503684W A SG11201503684W A SG 11201503684WA SG 11201503684W A SG11201503684W A SG 11201503684WA
- Authority
- SG
- Singapore
- Prior art keywords
- pyrimido
- diones
- quinoline
- nonsense mutation
- mutation suppressors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Inorganic Chemistry (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261736748P | 2012-12-13 | 2012-12-13 | |
| PCT/IB2013/060859 WO2014091446A1 (en) | 2012-12-13 | 2013-12-12 | Pyrimido [4,5-b]quinoline-4,5 (3h,10h)-diones as nonsense mutation suppressors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201503684WA true SG11201503684WA (en) | 2015-06-29 |
Family
ID=50030361
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201503684WA SG11201503684WA (en) | 2012-12-13 | 2013-12-12 | Pyrimido [4,5-b]quinoline-4,5 (3h,10h)-diones as nonsense mutation suppressors |
Country Status (24)
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104837490B (zh) | 2012-12-13 | 2017-10-03 | 诺华股份有限公司 | 作为无义突变抑制子的嘧啶并[4，5‑b]喹啉‑4，5(3H，10H)‑二酮 |
| SG11201609209YA (en) * | 2014-06-03 | 2016-12-29 | Novartis Ag | Naphthyridinedione derivatives |
| US9896448B2 (en) | 2014-06-03 | 2018-02-20 | Novartis Ag | Pyrimido[4,5-b]quinoline-4,5(3H, 10H)-dione derivatives |
| WO2015186061A1 (en) * | 2014-06-03 | 2015-12-10 | Novartis Ag | Pyridopyrimidinedione derivatives |
| US10960018B2 (en) * | 2016-04-15 | 2021-03-30 | The Uab Research Foundation | Methods and compounds for stimulating read-through of premature termination codons |
| WO2019173437A1 (en) * | 2018-03-06 | 2019-09-12 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Positive allosteric modulators of dopamine 1 receptor and method of use thereof |
| WO2019225625A1 (ja) * | 2018-05-23 | 2019-11-28 | 京都薬品工業株式会社 | リードスルー誘導剤およびその医薬用途 |
| WO2022053651A2 (en) | 2020-09-10 | 2022-03-17 | Precirix N.V. | Antibody fragment against fap |
| CA3208313A1 (en) | 2021-01-13 | 2022-07-21 | Monte Rosa Therapeutics Ag | Isoindolinone compounds |
| WO2023203135A1 (en) | 2022-04-22 | 2023-10-26 | Precirix N.V. | Improved radiolabelled antibody |
| KR20250034289A (ko) | 2022-05-02 | 2025-03-11 | 프리시릭스 엔.브이. | 사전 표적화 |
| WO2024194607A1 (en) | 2023-03-17 | 2024-09-26 | Tay Therapeutics Limited | Pyrimido[4,5-b][1,5]naphthyridine-4,5(3h,10h)-dione derivatives for the treatment of diseases associated with ptc mutations, such as e.g. cancer |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2884170B2 (ja) | 1989-08-24 | 1999-04-19 | 株式会社フジモト・ブラザーズ | ５−デアザフラビン系化合物を有効成分とする制癌剤 |
| WO1996028444A1 (en) * | 1995-03-15 | 1996-09-19 | Pfizer Inc. | 5,10-DIHYDROPYRIMIDO[4,5-b]QUINOLIN-4(1H)-ONE TYROSINE KINASE INHIBITORS |
| US6468990B1 (en) | 1999-05-17 | 2002-10-22 | Queen's University At Kingston | Method of inhibiting binding of nerve growth factor to p75 NTR receptor |
| AU2003249244A1 (en) | 2002-07-15 | 2004-02-02 | Combinatorx, Incorporated | Methods for the treatment of neoplasms |
| JP2007524596A (ja) | 2003-02-28 | 2007-08-30 | トランスフォーム・ファーマシューティカルズ・インコーポレイテッド | 共結晶医薬組成物 |
| PT3632902T (pt) | 2003-04-11 | 2021-09-15 | Ptc Therapeutics Inc | Composto de ácido 1,2,4-oxadiazole benzóico e a sua utilização para a supressão sem sentido e tratamento de doenças |
| EP2007783B1 (en) | 2006-04-03 | 2018-07-11 | Technion Research & Development Foundation Ltd. | Novel aminoglycosides and uses thereof in the treatment of genetic disorders |
| AU2007288198A1 (en) | 2006-08-23 | 2008-02-28 | Neurogen Corporation | Haloalkyl-substituted pyrimidinone derivatives |
| JP2011507910A (ja) * | 2007-12-21 | 2011-03-10 | ユニバーシティー オブ ロチェスター | 真核生物の寿命を変更するための方法 |
| EP2422817A1 (en) | 2010-07-29 | 2012-02-29 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Flavin-nucleic acid ligand conjugates |
| JP5877200B2 (ja) | 2010-08-05 | 2016-03-02 | ユニヴェルシテ ドゥ ドロワ エ サンテ ドゥ リール | ナンセンス突然変異による疾患の治療に有用な化合物及びその化合物を含む医薬組成物 |
| CN104837490B (zh) | 2012-12-13 | 2017-10-03 | 诺华股份有限公司 | 作为无义突变抑制子的嘧啶并[4，5‑b]喹啉‑4，5(3H，10H)‑二酮 |
-
2013
- 2013-12-12 CN CN201380064035.5A patent/CN104837490B/zh not_active Expired - Fee Related
- 2013-12-12 MX MX2015007562A patent/MX363437B/es unknown
- 2013-12-12 CN CN201710826258.0A patent/CN107569487A/zh active Pending
- 2013-12-12 AU AU2013358591A patent/AU2013358591B2/en not_active Ceased
- 2013-12-12 AP AP2015008441A patent/AP2015008441A0/xx unknown
- 2013-12-12 PE PE2015000911A patent/PE20151062A1/es not_active Application Discontinuation
- 2013-12-12 WO PCT/IB2013/060859 patent/WO2014091446A1/en active Application Filing
- 2013-12-12 CA CA2890692A patent/CA2890692A1/en not_active Abandoned
- 2013-12-12 EP EP13826612.7A patent/EP2931282B1/en active Active
- 2013-12-12 US US14/652,102 patent/US9649314B2/en not_active Expired - Fee Related
- 2013-12-12 JP JP2015547244A patent/JP6076498B2/ja not_active Expired - Fee Related
- 2013-12-12 IN IN3998DEN2015 patent/IN2015DN03998A/en unknown
- 2013-12-12 ES ES13826612T patent/ES2709034T3/es active Active
- 2013-12-12 KR KR1020157018231A patent/KR101760586B1/ko not_active Expired - Fee Related
- 2013-12-12 BR BR112015013535A patent/BR112015013535A2/pt not_active Application Discontinuation
- 2013-12-12 HK HK15110447.1A patent/HK1209637A1/xx unknown
- 2013-12-12 EA EA201591105A patent/EA028673B1/ru not_active IP Right Cessation
- 2013-12-12 SG SG11201503684WA patent/SG11201503684WA/en unknown
-
2015
- 2015-05-29 PH PH12015501216A patent/PH12015501216A1/en unknown
- 2015-06-04 IL IL239244A patent/IL239244A0/en unknown
- 2015-06-05 MA MA38157A patent/MA38157A1/fr unknown
- 2015-06-09 TN TNP2015000262A patent/TN2015000262A1/fr unknown
- 2015-06-10 CL CL2015001610A patent/CL2015001610A1/es unknown
- 2015-06-12 CU CUP2015000061A patent/CU20150061A7/es unknown
- 2015-06-12 CR CR20150314A patent/CR20150314A/es unknown
-
2017
- 2017-04-04 US US15/478,778 patent/US20170266189A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL239244A0 (en) | Pyrimido[4,5-b] quinoline-5, 4 (3h,10h) - discussions as suppressors of non-sense mutations | |
| IL240402A (en) | Tetrahydroimidazo derivative [d – 5,1] [4,1] oxazepine | |
| ZA201408843B (en) | Imidazo[1,2-b]pyridazine derivative as kinase inhibitor | |
| IL254224A0 (en) | 7-substituted 5-alkyl-[4,2,1]triazolo[5,1-a]pyrimidine derivatives as pde2 inhibitors | |
| IL234485A (en) | Compounds based on imidazo [2,1 – b] pyridazine | |
| EP2968311A4 (en) | OXAZOLO [5,4-C] CHINOLIN-2-ON COMPOUNDS AS BROMODOMENA INHIBITORS | |
| IL243092B (en) | New triazolo[d–4,5]pyrimidine histories | |
| AP2014007820A0 (en) | PDE9 inhibitors with imidazo triazinone backbone | |
| LT2855480T (lt) | Pteridinai kaip fgfr inhibitoriai | |
| ZA201407828B (en) | Bicyclic pyrazinone derivatives | |
| PT3129374T (pt) | (5,6-dihidro)pirimido[4,5-e] indolizinas | |
| ZA201406323B (en) | Triazolo[4,5-d]pyrimidine derivatives | |
| PT2694513E (pt) | Derivados de pirazolopirimidina | |
| ZA201507151B (en) | Antiviral indolo[2,3-b]quinoxaline | |
| IL236808B (en) | Piperazino[1,2-a]indol-1-ones and [1,4]diazepino[1,2-a]indol-1-one | |
| GB201215033D0 (en) | Diazepinone derivatives | |
| GB2501283B (en) | Microbiological safety cabinets | |
| GB201211756D0 (en) | Novel isothiazolo [4,3-b]pyridines | |
| GB201219129D0 (en) | Triazolo(4,5-d)pyrmindine compounds | |
| AU344103S (en) | Modular outdoor seating | |
| GB201221462D0 (en) | Novel isothiazolo[5,4-b]pyridines | |
| GB201213663D0 (en) | Novel isothiazolo[5,4-b]pyridines | |
| PH22012000559U1 (en) | Multi-purpose stool |